Biotech Movers - a January '23 Surprise

Components Performance/Risk
Period Return
37.6%
Return Rank
Strong
Risk Exposure
Above Average

The J.P. Morgan Healthcare Conference - January 9-12, 2023 - in San Francisco is in the news

 The conference is introduced by J.P. Morgan as the largest and most informative healthcare investment symposium in the industry which connects global industry leaders, emerging fast-growth companies, innovative technology creators and members of the investment community

 

It is an opportunity to evaluate some of the high performing biotechnology shares since late 2022 

Following a very difficult year with extreme share downgrades, the sector appears to be on the mend, with less focus on 'far-out' promising research, more interest in short-to-medium term commercial launches of innovative pharmaceuticals

A sharp uptick of the theme, +30% on average of the components in a single month, as of January 12, looks promising

Our selection of 26 stocks is limited (the benchmark - iShares Biotechnology ETF is invested in more than 250 biotech shares)

The theme includes companies in a variety of  industries active within the sector and over a broad range of market capitalizations

 

Very large firms such as Moderna and Beigene Invalid tag asset have been excluded of the selection

The continuous rise of their stock price since October 2022 may be a sign of things to come - a solid recovery of biotechnology stocks is in the cards

 

Trends over the past two weeks has been especially notable

  • Set your preferred timeframe for analysis on the drop-down menu at the top right
  • Check price charts on "Asset Infos" by clicking on name or ticker

 

Projections remain subject to brutal reversals in this volatile sector and trends should be evaluated closely

By bookmarking the theme, keep track of the trend and performing shares of our selection

Performance History
Components Performance/Risk
Weights by Industry
Industry Performance/Risk